Issue 2/2009
Content (27 Articles)
Cost-effective analyses in Breast Cancer Research and Treatment
Marc E. Lippman, Stephen Ethier, Daniel F. Hayes
Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers
Jan P. A. Baak, Einar Gudlaugsson, Ivar Skaland, Lydia Hui Ru Guo, Jan Klos, Tone Hoel Lende, Håvard Søiland, Emiel A. M. Janssen, Axel zur Hausen
Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review
Jennifer Flemming, Yolanda Madarnas, Jacob A. Franek
Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model
Jiangbing Zhou, Hao Zhang, Peihua Gu, Joseph B. Margolick, Deling Yin, Ying Zhang
Systemic chemokine levels in breast cancer patients and their relationship with circulating menstrual hormones
Shirley M. Potter, Roisin M. Dwyer, Catherine E. Curran, Emer Hennessy, Kate A. Harrington, Damian G. Griffin, Michael J. Kerin
The androgen metabolite 5α-androstane-3β,17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance
Matthew J. Sikora, Kevin E. Cordero, Jose M. Larios, Michael D. Johnson, Marc E. Lippman, James M. Rae
Insulin receptor substrate 1 modulates the transcriptional activity and the stability of androgen receptor in breast cancer cells
Marilena Lanzino, Cecilia Garofalo, Catia Morelli, Maria Le Pera, Ivan Casaburi, Michael J. McPhaul, Eva Surmacz, Sebastiano Andò, Diego Sisci
No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers
Amanda B. Spurdle, Andrew J. Deans, David Duffy, David E. Goldgar, Xiaoqing Chen, Jonathan Beesley, Douglas F. Easton, Antonis C. Antoniou, Susan Peock, Margaret Cook, Katherine L. Nathanson, Susan M. Domchek, Grant A. MacArthur, Georgia Chenevix-Trench
Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families
Thomas v. O. Hansen, Lars Jønson, Anders Albrechtsen, Mette K. Andersen, Bent Ejlertsen, Finn C. Nielsen
Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients
Wen-Jin Yin, Jin-Song Lu, Gen-Hong Di, Yan-Ping Lin, Li-Heng Zhou, Guang-Yu Liu, Jiong Wu, Kun-Wei Shen, Qi-Xia Han, Zhen-Zhou Shen, Zhi-Ming Shao
Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer
Hye-Suk Han, Jungsil Ro, Keun Seok Lee, Byung-Ho Nam, Jung Ae Seo, Dae Hee Lee, Honggi Lee, Eun Sook Lee, Han Sung Kang, Seok Won Kim
Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy
Qifeng Yang, Meena S. Moran, Bruce G. Haffty
Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors
Olivier Brouckaert, Saskia Pintens, Vanya Van Belle, Sabine Van Huffel, Edward Camerlynck, Frédéric Amant, Karin Leunen, An Smeets, Patrick Berteloot, Erik Van Limbergen, Julie Decock, Wouter Hendrickx, Caroline Weltens, Walter Van den Bogaert, Isabelle Vanden Bempt, Maria Drijkoningen, Robert Paridaens, Hans Wildiers, Ignace Vergote, Marie-Rose Christiaens, Patrick Neven
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
T. Byrski, T. Huzarski, R. Dent, J. Gronwald, D. Zuziak, C. Cybulski, J. Kladny, B. Gorski, J. Lubinski, S. A. Narod
Psychological impact of recall in high-risk breast MRI screening
Suzanne M. O’Neill, Wendy S. Rubinstein, Stephen F. Sener, Scott M. Weissman, Anna C. Newlin, Daniel K. West, David B. Ecanow, Alfred W. Rademaker, Robert R. Edelman
The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer
Rupert Bartsch, Brigitte Mlineritsch, Michael Gnant, Thomas Niernberger, Ursula Pluschnig, Richard Greil, Catharina Wenzel, Paul Sevelda, Josef Thaler, Margaretha Rudas, Michael Pober, Christoph C. Zielinski, Guenther G. Steger
Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose?
Catharina E. Jacobi, Geertruida H. de Bock, Bob Siegerink, Christi J. van Asperen
CYP2C19*17 is associated with decreased breast cancer risk
Christina Justenhoven, Ute Hamann, Christiane B. Pierl, Christian Baisch, Volker Harth, Sylvia Rabstein, Anne Spickenheuer, Beate Pesch, Thomas Brüning, Stefan Winter, Yon-Dschun Ko, Hiltrud Brauch
BRCA1 promoter methylation is associated with increased mortality among women with breast cancer
Xinran Xu, Marilie D. Gammon, Yujing Zhang, Timothy H. Bestor, Steven H. Zeisel, James G. Wetmur, Sylvan Wallenstein, Patrick T. Bradshaw, Gail Garbowski, Susan L. Teitelbaum, Alfred I. Neugut, Regina M. Santella, Jia Chen
High-resolution melting analysis for rapid screening of BRCA1 and BRCA2 Spanish mutations
Inmaculada de Juan, Eva Esteban, Sarai Palanca, Eva Barragán, Pascual Bolufer
A retrospective study of quality of life in a community sample of patients with early stage breast cancer
Mark S. Walker, Lee S. Schwartzberg, Edward J. Stepanski, Barry V. Fortner
Pattern of metastatic spread in triple-negative breast cancer
Rebecca Dent, Wedad M. Hanna, Maureen Trudeau, Ellen Rawlinson, Ping Sun, Steven A. Narod
Dihydrofolate reductase (DHRF) 19-bp intron-1 deletion and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms in breast cancer
Ragip Çam, Aydan Eroglu, Yonca Egin, Nejat Akar
The sensitivity of BRCA1 mutation carriers to ionising radiation: questions of methodology
Magdalena Chechlinska, Radoslawa Nowak
Link between insulin and metabolic disorders in cancer: does leptin play a key role?
Noemi Malandrino, Lorenzo Leggio, Giovanni Addolorato, Giovanni Gasbarrini, Esmeralda Capristo